GlassScriptPhysician profile
Dennis Edward Rademaker
NPI 1457328411
$4,393.40
in general payments reported to CMS, 2019-2025
27 companies · $687 in 2025
The $687 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $587 · 2021: $345 · 2022: $409 · 2023: $329 · 2024: $625 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583 · Education: $57.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.48 |
| Education | $57.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $683.94 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $635.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Alk-Abello, INC | $587.09 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Optinose US, INC. | $536.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $306.44 | 2019-2025 | |
| Csl Behring | $257.32 | 2019-2024 | Hizentra |
| Covis Pharma Gmbh | $195.02 | 2019-2021 | |
| Amgen INC. | $191.04 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $177.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.88 | 2020-2025 | Cuvitru, Hyqvia |
| Shire North American Group INC | $113.22 | 2019 | |
| Genzyme Corporation | $89.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $73.27 | 2019-2025 | Dupixent |
| Kaleo, INC. | $72.85 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $62.52 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.01 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $44.86 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $24.33 | 2022 | |
| Hospira, INC. | $22.94 | 2019 | |
| Alcon Vision LLC | $18.40 | 2024 | Total30 |
| Genentech USA, INC. | $18.13 | 2019 | |
| Kedrion Biopharma, INC. | $17.72 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Philips North America LLC | $16.02 | 2019 | |
| Merck Sharp & Dohme LLC | $15.49 | 2023 | |
| Mallinckrodt Enterprises LLC | $14.31 | 2019 | |
| Hikma Pharmaceuticals USA | $14.00 | 2023 | Ryaltris |
| Phadia US INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Rademaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.